The antidyslipidemic market is approaching further genericization when in 2011, leading statin brand Lipitor will lose patent exclusivity and trigger decline of the entire market value. Clinical trials continue to produce an evidence base that justifies the dominant position held by statins and extends their reach into further indications.
Reasons to Purchase
*Quantify and qualify antidyslipidemic sales in each of the seven major markets for 20062019
*Examine the future performance of leading antidyslipidemic brands and the growth of generics
*Understand the commercial landscape and challenges faced by pipeline agents
#N/A
Other selected research from the 'R&D' category:
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 40 companies plus partners who are today developing 31 Hedgehog pathway targeting drugs in 123 developmental projects in cancer across 40 different targets. In addition, there is 1 suspended drug and another 19 drugs where development has been ceased. Learn More
Translational Medicine - Drug Development Transformed? (Market Focus)